CLClinicLens

Hematology

Low-dose ruxolitinib for graft-versus-host disease prevention in haploidentical haematopoietic stem-cell transplantation: a multicentre, open-label, randomised,

Acute graft-versus-host disease (GVHD) remains a major cause of morbidity and mortality after haploidentical haematopoietic stem-cell transplantation (HSCT). Ruxolitinib, a Janus kinase (JAK) 1/2 inhibitor with established activity in steroid-refractory GVHD, has shown promise fo

Medical Literature · Updated

← Back to articles
This standalone article is served from the ClinicLens content archive.

If the embedded page does not load in your browser, open it directly.